Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer

Autor:	Colby S. Shemesh, Pascal Chanu, Kris Jamsen, Russ Wada, Gianluca Rossato, Francis Donaldson, Amit Garg, Helen Winter, Jane Ruppel, Xin Wang, Rene Bruno, Jin Jin, Sandhya Girish
Jazyk:	angličtina
Rok vydání:	2019
Předmět:	Atezolizumab Cancer immunotherapy Clinical pharmacology Exposure-safety Immune checkpoint inhibitor Pediatric oncology Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Druh dokumentu:	article
ISSN:	2051-1426
DOI:	10.1186/s40425-019-0791-x
Popis:	Abstract Background The iMATRIX-atezolizumab study was a phase I/II, multicenter, open-label study designed to assess the safety and pharmacokinetics of atezolizumab in pediatric and young adult patients. We describe the pharmacokinetics (PK), exposure-safety, and immunogenicity of atezolizumab in pediatric and young adults with metastatic solid tumors or hematologic malignancies enrolled in this study. Methods Patients aged
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/b996c2b9893a413b9905987d3a8dc5c2 Zobrazit plný text záznamu Full text from SpringerLink View record in DOAJ